Top

Journal of Gastrointestinal Surgery

Published in:

01-02-2012 | 2011 SSAT Plenary Presentation

Budd–Chiari Syndrome Revisited: 38 Years’ Experience with Surgical Portal Decompression

Authors: Marshall J. Orloff, Jon I. Isenberg, Henry O. Wheeler, Pat O. Daily, Barbara Girard

Published in: Journal of Gastrointestinal Surgery | Issue 2/2012

Abstract

Objective

Ten years ago, we reported our results with what remains as the largest clinical experience with surgical portal decompression for Budd–Chiari syndrome (BCS) in the West. Since then, our series has expanded to 77 patients, and there has been an explosion of interest in and publications about BCS. The objectives of this study are to assess the validity of our observations and conclusions regarding BCS reported 10 years ago by expansion of our series of patients and observations of outcomes over an additional decade of close follow-up.

Methods

Seventy-seven patients with BCS were allocated to three groups: group I, 39 had hepatic vein occlusion alone, treated by side-to-side portacaval shunt (SSPCS); group II, 26 had inferior vena cava occlusion treated by mesoatrial shunt in eight and combined SSPCS and cavoatrial shunt (CAS) in 18; and group III, 12 had decompensated cirrhosis too late for portal decompression who were listed for liver transplantation (LT). An extensive diagnostic workup included angiography with pressure measurements and needle liver biopsy. Follow-up was 100%, lasting 5–38 years.

Results

In group I, long-term survival is 95% with 36 free of ascites, leading lives of good quality 5–38 years post-SSPCS. In group II, mesoatrial shunt was discontinued after 1990 because of a high failure rate, but combined SSPCS-CAS has resulted in 100% survival for 5–25 years. In group III, six patients (50%) are alive and well for more than 5 years post-LT. Serial liver biopsies following portal decompression have shown long-term reversal of the lesions of BCS.

Conclusions

Long-term survival following portal decompression of BCS in the West has not been equaled by any other form of therapy, medical or surgical. It is imperative to perform surgical portal decompression early in the course of BCS in order to avoid irreversible liver damage.

Orloff MJ, Daily PO, Orloff SL, Girard B, Orloff MS. Twenty-seven years’ experience with surgical treatment of Budd–Chiari syndrome. Ann Surg 2000; 232:340–352.PubMedCrossRef

Orloff MJ, Johansen KH. Treatment of Budd–Chiari syndrome by side-to-side portacaval shunt: experimental and clinical results. Ann Surg 1978; 188:494–512.PubMedCrossRef

Orloff MJ, Girard B. Long-term results of treatment of Budd–Chiari syndrome by side-to-side portacaval shunt. Surg Gynecol Obstet 1989; 168:33–41PubMed

Patel RK, Lea NC, Heneghan MA, Westwood NB, Milojkovic D, Hanigaikumar M, Yallop D, Arya R, Pagliuca A, Gäken J, Wendon J, Heaton ND, Mufti GJ Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd–Chiari syndrome. Gastroenterology 2006; 130:2031–2038.PubMedCrossRef

Kralovics R, Passamonti F, Buser AS, Teo S-S, Tiet R, Passweg JR; Tichelli A, Cazzola M, Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352:1779–1790.PubMedCrossRef

Sozer S, Fiel MI, Schiano T, Xu M, Mascarenhas J, Hoffman R, Ebert BL, Wernig G, Huntly BJP, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D’Andrea A, Fröhling S, Döhner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd–Chiari syndrome. Blood 2009; 113:5246–5249.PubMedCrossRef

Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D’Andrea A, Fröhling S, Döhner K, Marynen P, Vandenberghe P, et al. Activating mutation in the tyrosine kinasae JAK2 in polycthemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7:387–397.PubMedCrossRef

Primignani M, Barosi G, Bergamaschi G, Gianelli U, Fabris F, Reati R, Dell’Era A, Bucciarelli P, Mannuccio Mannucci P. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006; 44:1528–1534.PubMedCrossRef

Orloff MJ, Orloff SL, Orloff MS. Portacaval shunts: side-to-side and end-to-side. In Clavien P-A, Saar MG, Fong Y, eds. Atlas of Upper Gastrointestinal and Hepato-Pancreato-Biliary Surgery. Berlin-Heidelberg: Springer-Verlag, 2007, pp 687–702.CrossRef

10.

Orloff MJ, Orloff MS. Treatment of Budd–Chiari syndrome due to inferior vena cava occlusion by combined portal and vena cava decompression. Amer J Surg 1992; 163:137–143.PubMedCrossRef

11.

Orloff MJ, Isenberg JI, Wheeler HO, Haynes KS, Jinich-Brook H, Rapier R, Vaida F, Hye RJ. . Portal-systemic encephalopathy in a randomized controlled trial of endoscopic sclerotherapy versus emergency portacaval shunt treatment of acutely bleeding esophageal varices in cirrhosis. Ann Surg 2009; 250:598–610.PubMed

12.

Orloff MJ, Orloff MS, Orloff SL. Budd–Chiari syndrome and veno-occlusive disease. In Blumgart LH, Belghiti J, Jarnagin WR, et al, eds. Philadelphia: Saunders Elsevier, Surgery of the Liver, Biliary Tract and Pancreas, 4th ed., 2007, pp 687–702.

13.

Ahn SS, Yellin A, Sheng FC. Selective surgical therapy of Budd–Chiari syndrome provides superior survivor rates than conservative medical management. J Vasc Surg 1987; 58:28–37.

14.

McCarthy PM, van Heerden JA, Adson MA, Schafer LW; Wiesner RH. The Budd–Chiari syndrome: medical and surgical management of 30 patients. Arch Surg 1985; 120:657–662.PubMedCrossRef

15.

Bismuth H, Sherlock DJ. Portosystemic shunting versus liver transplantation for the Budd–Chiari syndrome. Ann Surg 1991; 214:581–589.PubMedCrossRef

16.

Hemming AW, Langer B, Greig P, Taylor BR, Adams R, Heathcote EJ. Treatment of Budd–Chiari syndrome with portosystemic shunt or liver transplantation. Am J Surg 1996; 171:176–181.PubMedCrossRef

17.

Panis Y, Belghiti J, Valla D, Benhamou JP, Fékété F. Portosystemic shunt in Budd–Chiari syndrome: long-term survival and factors effecting shunt patency in 25 patients in Western countries. Surgery 1994; 115:276–281.PubMed

18.

Pezzuoli G, Spina GP, Opocher E, Galeotti F, Zannini P. Portacaval shunt in the treatment of primary Budd–Chiari syndrome. Surgery 1985; 98:319–323.PubMed

19.

Millikan WJ Jr, Henderson JM, Sewell CW, Guyton RA, Potts JR III, Cranford CA Jr, Cramer AR, Galambos JT, Warren WD. Approach to the spectrum of Budd–Chiari syndrome: which patients require portal decompression? Am J Surg 1985; 149:167–176.PubMedCrossRef

20.

Wang ZG, Zhu Y, Wang SH, PU LP, Du YH, Zhang H, Yuan C, Chen Z, Wei ML, Pu LQ, et al. Recognition and management of Budd–Chiari syndrome: report of one hundred cases. J Vasc Surg 1989; 10:149–156.PubMed

21.

Vons C, Smadja C, Bourtstyn E, Szekely A-M, Bonnet P, Franco D. Results of portal systemic shunts in Budd–Chiari syndrome. Ann Surg 1986; 203:366–370.PubMedCrossRef

22.

Klein AS, Sitzmann JV, Coleman J, Herlong FH, Cameron JL. Current management of the Budd–Chiari syndrome. Ann Surg 1990; 212:144–149.PubMedCrossRef

23.

Henderson JM, Warren WD, Millikan Jr WJ, Galloway JR, Kawasaki S, Stahl RL, Hertzler G. Surgical options, hematologic evaluation, and pathologic changes in Budd–Chiari syndrome. Am J Surg 1990; 159:41–50.PubMedCrossRef

24.

Dowling JB. Ten years’ experience with mesocaval grafts. Surg Gynecol Obstet 1979; 149:518–522.PubMed

25.

Terpstra OT, Ausema B, Bruining HA, Laméris, JS, Reuvers CB, Schalm SW, van Urk H, Wilson JHP. Late results of mesocaval interposition shunting for bleeding oesophageal varices. Br J Surg 1987; 74:787–780.PubMedCrossRef

26.

Smith RB III, Warren WD, Salam AA, Millikan WJ, Ansley JD, Galambos JT, Kutner M, Bain RP. Dacron® interposition shunts for portal hypertension. An analysis of morbidity correlates. Ann Surg 1980; 192:9–17.PubMedCrossRef

27.

Fletcher MS, Dawson JL, and Williams R. Long-term follow-up of interposition mesocaval shunting in portal hypertension. Br J Surg 1981; 68:485–487.PubMedCrossRef

28.

Jannsen HLA, Garcia-Pagan J-C, Elias E, Mentha G, Hadengue A, Valla D-C, for the European Group for the Study of Vascular Disorders of the Liver Budd–Chiari syndrome: a review by an expert panel. J Hepatology 2003; 38:364–371.CrossRef

29.

Plessier A, Valla D-C. Budd–Chiari syndrome. Semin Liver Dis 2008; 28:259–269.PubMedCrossRef

30.

Hoekstra J, Janssen HL. Vascular liver disorders (1): diagnosis, treatment, and prognosis of Budd–Chiari syndrome. Neth J Med 2008; 66:334–339.PubMed

31.

Amarepurkar DN, Ponamiya SJ, Patel ND. Changing spectrum of Budd–Chiari syndrome in India with special reference to non-surgical treatment. Wld J Gastroenterol 2008; 14:278–285.CrossRef

32.

DeLeve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology 2009; 49:1729–1764.PubMedCrossRef

33.

Bachet J-B, Condat B, Hagegl H, Plessier A, Consigny Y, Belghiti J, Valla D. Long-term portosystemic shunt patency as a determinant of outcome in Budd–Chiari syndrome. J Hepatol 2007; 46:60–68.PubMedCrossRef

34.

Menon KVN, Shah V, Kamath PS. The Budd–Chiari syndrome. N Engl J Med 2004; 350:578–585.PubMedCrossRef

35.

Montano-Loza AJ, Tandon P, KnetDman N, Bailey R, Bain VG. Rotterdam score predicts early mortality in Budd–Chiari syndrome, and surgical shunting prolongs transplant-free survival. Aliment Pharmacol Ther 2009; 30:1060–1069.PubMedCrossRef

36.

Singhal D, de Castro S, Goyal N, Gouma DJ, Chaudhary A, van Gulik TM. Current role of portosystemic shunt surgery in the management of hepatic venous outflow obstruction. Dig Surg 2006; 23:358–369.PubMedCrossRef

37.

Zimmerman MA, Cameron AM, Ghobrial AM. Budd–Chiari syndrome. Clin Liver Dis 2006; 10:259–273.PubMedCrossRef

38.

Xu PQ, Xiu-Xian M, Xue-Xiang Y, Liu-Shun F, Xiao-Wei D, Yong-Fu Z, et al. Surgical treatment of 1360 cases of Budd–Chiari syndrome: a 20-year experience. Hepatobiliary Pancreatic Dis Int 2004; 3:391–394.

39.

Wang ZG, Feng JZ, Meng QY, Li XQ. Evolution of management for Budd–Chiari syndrome: a team’s view from 2564 patients. ANZ J Surg 2005; 75:55–63.PubMedCrossRef

40.

Warren RL, Schlant RC, Wenger NK, Galambos JT. Treatment of Budd–Chiari syndrome with streptokinase. Gastroenterology 1972; 62:200.

41.

Barrault C, Plessier A, Valla D, Condat B. Nonsurgical treatment of Budd–Chiari syndrome: a review. Gastroenterol Clin Biol 2004; 28:40–49.PubMedCrossRef

42.

Sharma S, Texeira A, Texeira P, Elias E, Wilde J, Olliff SP. Pharmacological thrombolysis in Budd–Chiari syndrome: a single centre experience and review of the literature. J Hepatol 2004; 40:172–180.PubMedCrossRef

43.

Murad SD, Plessier A, Hernandez-Guerra M, Fabris F, Chundamannil E, Eapen CE, Bahr MJ, Trebicka J, Morard I, Lasser L, Heller J, Hadengue A, Langlet P, Miranda H, Primignani M, Elias E, Leebeek FW, Rosendaal FR, Garcia-Pagan J-C, Dominique C, Valla DCM, Janssen HLA, and for EN-Vie (European Network for Vascular Disorders of the Liver. Etiology, management, and outcome of the Budd–Chiari syndrome. Ann Intern Med 2009; 151:167–175.

44.

Valla D-C. The diagnosis and management of the Budd–Chiari syndrome: consensus and controversies. Hepatology 2003; 38:793–803.PubMed

45.

Rössle M, Olschewski M, Siegerstetter V, Berger E, Kurz K, Grandt D. The Budd–Chiari syndrome: outcome after treatment with the transjugular intrahepatic portosystemic shunt. Surgery 2004; 135:394–403.PubMedCrossRef

46.

Rössle M, Siegerstetter V, Euringer W, Olschewski M, Kromeier J, Kurz K, Langer M. The use of polytetrafluorethylene-covered stent graft for transjugular intrahepatic portosystemic shunt (TIPS): long-term follow-up of 100 patients. Acta Radiol 2006; 47:660–666.PubMedCrossRef

47.

Garcia-Pagan JC, Heydtmann M, Raffa S, Plessier A, Murad S, Fabris F, Vizzini G, Gonzales Abraldes J, Olliff S, Nicolini A, Luca A, Primignani M, Janssen HLA, Valla D, Elias E, Bosch J, and BCS-TIPS Group. TIPS for Budd–Chiari syndrome: long-term results and prognostic factors in 124 patients. Gastroenterology 2008; 135:808–815.PubMedCrossRef

48.

Mentha G, Glostra E, Majno PE, Bechstein WO, Neuhaus P, O’Grady J, Praseedom RK, Burroughs AK, Le Treut YP, Kirkegaard P, Rogiers X, Ericzon B-G, Hockerstedt K, Adam R, Klempnauer J. Liver transplantation for Budd–Chiari syndrome: a European study on 248 patients from 51 centers. J Hepatol 2006; 44;520–528.PubMedCrossRef

49.

Segev DL, Nguyen GC, Locke JE, Simpkins CE, Montgomery RA, Maley WR, Thuluvath PJ. Twenty years of liver transplantation for Budd–Chiari syndrome: a national registry analysis. Liver Transpl 2007; 13:1285–1294.PubMedCrossRef

50.

Plessier A, Sibert A, Cosigny Y, Hakime A, Zappa M, Denninger M-H, Condat B, Farges O, Chagneau C, de Ledinghen V, Francoz C, Sauvanet A, Vilgrain V, Belghiti J, Durand F, Valla D. Aiming at minimal invasiveness as a therapeutic strategy for Budd–Chiari syndrome. Hepatology 2006; 44:1308–1316.PubMedCrossRef

51.

de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV Consensus Workshop on Methodology of Diagnosis and Therapy in Portal Hypertension. J Hepatol 2005; 43:167–176.PubMedCrossRef

52.

Srinivasin P, Rela M, Prachalias A, Muiesan P, Portmann B, Jeelani-Mufti G, Pagliuca A, O’Grady J, Heaton N. Miscellaneous Article. Liver transplantation for Budd–Chiari syndrome. Transplantation 2002; 73:973–977.CrossRef

53.

Melear JM, Goldstein RM, Levy MF, Molmenti EP, Cooper B, Netto GJ, Klintmalm GB, Stone MJ. Hematologic aspects of liver transplantation for Budd–Chiari syndrome with special reference to myeloproliferative disorders. Transplantation 2002; 74:1090–1095.PubMedCrossRef

54.

Ringe B, Lang H, Oldhafer K-J, Gebel M, Flemming P, Georgii A, Borst H-G, Pichlmayr R. Which is the best surgery for Budd–Chiari syndrome: venous decompression or liver transplantation? A single-center experience with 50 patients. Hepatology 1995; 21:1337–1344.PubMedCrossRef

55.

Knoop M, Lemmens H-P, Bechstein WO, Blumhardt G, Schattenfroh N, Keck H, Neuhaus P. Treatment of the Budd–Chiari syndrome with orthotopic liver transplantation and long-term anticoagulation. Clin Transpl 1994; 8:67–72.

56.

Galti JS, Langnas AN, Donovan JP, Schafer DF, Sorrell MF, Zetterman RK, Fox IJ, Heffron TG, Shaw BW Jr. The Budd–Chiari syndrome: a therapeutic quandary. Gastroenterology 1993; 104:A904.

57.

Shaked A, Goldstein RM, Klintmalm GB, Drazan K, Husberg B, Busuttil RW. Portosystemic shunt versus orthotopic liver transplantation for the Budd–Chiari syndrome. Surg Gynecol Obstet 1992; 174:453–459.PubMed

58.

Halff G, Todo S, Tzakis AG, Gordon RD, Starzl TE. Liver transplantation for the Budd–Chiari syndrome. Ann Surg 1990; 211:43–49.PubMedCrossRef

59.

Iwatsuki S, Kishida A, Starzl T. Liver transplantation for Budd–Chiari syndrome. In Proceedings of the second international symposium on Budd–Chiari syndrome, Kyoto, Japan, 1991:VIPL-2.

60.

Sakai Y, Wall WJ. Liver transplantation for Budd–Chiari syndrome: a retrospective study. Jap J Surg 1994; 24:49–53.CrossRef

61.

Jamieson NV, Williams R, Calne RY. Liver transplantation for Budd–Chiari syndrome, 1976–1990. Ann Chir 1991; 45:362–365.PubMed

62.

Ulrich F, Pratschke J, Neumann U, Pascher A, Puhl G, Fellmer P, Weiss S, Jonas S, Neuhaus P. Eighteen years of liver transplantation experience in patients with advanced Budd–Chiari syndrome. Liver Transpl 2008; 14:144–150.PubMedCrossRef

63.

Cruz E, Ascher NL, Roberts JP, Bass NM, Yao FT. High incidence of recurrence and hematologic events following liver transplantation for Budd–Chiari syndrome. Clin Transplant 2005; 19:501–506.PubMedCrossRef

Title: Budd–Chiari Syndrome Revisited: 38 Years’ Experience with Surgical Portal Decompression
Authors: Marshall J. Orloff
Jon I. Isenberg
Henry O. Wheeler
Pat O. Daily
Barbara Girard
Publication date: 01-02-2012
Publisher: Springer-Verlag
Published in: Journal of Gastrointestinal Surgery / Issue 2/2012
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-011-1738-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Budd–Chiari Syndrome Revisited: 38 Years’ Experience with Surgical Portal Decompression

Abstract

Objective

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2012

Cholecystectomy in the Very Elderly—Is 90 the New 70?

Genetic Deletion of 5-Lipoxygenase Increases Tumor-Infiltrating Macrophages in ApcΔ468 Mice

Is there a Role for Surgery with Adequate Nodal Evaluation Alone in Gastric Adenocarcinoma?

Integration of 3D Volumetry, Portal Vein Transection and In Situ Split Procedure: A New Surgical Strategy for Inoperable Liver Metastasis

Activation of the BMP4 Pathway and Early Expression of CDX2 Characterize Non-specialized Columnar Metaplasia in a Human Model of Barrett’s Esophagus

Molecular Mechanism Underlying the Detection of Colorectal Cancer by 18F-2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography